(1) 代谢转运系统的调控机理及药物处置
(2) PBPK模型
(3) 创新药物药代动力学

1、科研项目
（1）国家自然科学基金委员会，面上项目，82173884，肝损伤引起肠、肝、肾和脑有机阳离子转运体功能与表达差异性改变及其在脑硫胺素缺乏中作用，2022-01-01 至 2025-12-31，55万元，在研，主持
（2）国家自然科学基金委员会，面上项目，81673505，糖尿病下调肝视黄醇脱氢酶和上调视黄醛脱氢酶活性与表达机制及其在肝胰岛素抵抗和糖尿病中作用，2017-01-01 至 2020-12-31，50万元，已结题，主持
（3）国家自然科学基金委员会，面上项目，81473273，基于CYP3A等CYP450酶活性诱导诠释阿托伐他汀等他汀类药物诱发新生糖尿病和加重糖尿病症状的作用及机制，2015-01-01 至 2018-12-31，70万元，已结题，主持
（4）国家自然科学基金委员会，青年基金，81102503，基于胰高血糖素样肽-1释放调控诠释人参二醇型皂苷抗糖尿病作用及其机制，2012-01-01 至 2014-12-31，25万元，已结题，主持
2、学术获奖
（1）2018-08，刘昌孝优秀青年科技工作者奖，排名第一

1.Hong S, Li S, Meng X, Li P, Wang X, Su M, Liu X*, Liu L*. Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin. Acta Pharm Sin B. 2022. doi: 10.1016/j.apsb.2022.06.010. IF: 14.903
2.Liu P, Jiang L, Kong WM, Xie QS, Li P, Liu XN, Zhang JY, Liu M, Wang Z, Zhu L, Yang Y, Zhou Y, Zou JJ*, Liu XD*, Liu L*. PXR activation impairs hepatic glucose metabolism partly via inhibiting HNF4α-GLUT2 pathway. Acta Pharm Sin B. 2022; 12(5): 2391-2405. IF: 14.903
3.Yang HY, Liu M, Sheng Y, Zhu L, Jin MM, Jiang TX, Yang L, Liu PH, Liu XD*, Liu L*. All-trans retinoic acid impairs glucose-stimulated insulin secretion by activating the RXR/SREBP-1c/UCP2 pathway. Acta Pharmacol Sin. 2022; 43(6):1441-1452. IF: 7.169
4.Yang Y, Zhang Z, Li P, Kong W, Liu X*, Liu L*. A Whole-body physiologically based pharmacokinetic nodel characterizing interplay of OCTs and MATEs in intestine, liver and kidney to predict drug-drug interactions of metformin with perpetrators. Pharmaceutics. 2021; 13(5): 698. IF:6.525.
5.Wu T, Sheng Y, Qin YY, Kong WM, Jin MM, Yang HY, Zheng XK, Dai C, Liu M, Liu XD*, Liu L*. Bile duct ligation causes opposite impacts on the expression and function of BCRP and P-gp in rat brain partly via affecting membrane expression of ezrin/radixin/moesin proteins. Acta Pharmacol Sin. 2021; 42(11):1942-1950. IF: 7.169
6.Li P, Huang J, Geng D, Liu P, Chu Z, Zou J*, Yang G*, Liu L*. Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase. Frontiers in Pharmacology. 2020; 11: 588286. IF: 5.988.
7.Wang Z, Yang H, Xu J, Zhao K, Chen Y, Liang L, Li P, Chen N, Geng D, Zhang X, Liu X*, Liu L*. Prediction of atorvastatin pharmacokinetics in high-fat diet and low-dose streptozotocin induced diabetic rats using a semi-physiologically based pharmacokinetic model involving both enzymes and transporters. Drug Metab Dispos. 2019; 47(10):1066-1079. IF: 3.579.
8.Chen Y, Zhao K, Liu F, Li Y, Zhong Z, Hong S, Liu X*, Liu L*. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model. Drug Metab Dispos. 2018; 46(6): 897-907. IF: 3.579.
9.Sun B, Zhong Z, Wang F, Xu J, Xu F, Kong W, Ling Z, Shu N, Li Y, Wu T, Zhang M, Zhu L, Liu X*, Liu L*. Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation. Biochem Pharmacol. 2018; 150:108-119. IF: 6.100.
10.Wang F, Miao MX, Sun BB, Wang ZJ, Tang XG, Chen Y, Zhao KJ, Liu XD*, Liu L*. Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp. Acta Pharmacol Sin. 2017; 38(11): 1554-1565. IF: 7.169

研究团队
刘晓东 教授
刘 李 教授
杨捍宇 博士后